Triple-negative breast cancer: Molecular subtypes and targeted therapy

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 1, 2014, Pages 34-40

  Hirshfield, Kim M ^a   Ganesan, Shridar ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Androgen receptor; Brca1; triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; ANTIANDROGEN; BEVACIZUMAB; BICALUTAMIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 12; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM; PROGESTERONE RECEPTOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; VELIPARIB;

ANTIANDROGEN THERAPY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DISTANT METASTASIS FREE SURVIVAL; DNA REPAIR; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891851844     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000038     Document Type: Review

References (39)

1. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560-569 (Pubitemid 44200649)
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-8423 (Pubitemid 36842560)
4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70
5. Azim HA Jr, Michiels S, Zagouri F, et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013; 24:647-654
6. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767
7. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66:4636-4644
8. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68
9. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basallike breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009; 117:273-280
10. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24:4660-4671 (Pubitemid 41032603)
11. Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19:5533-5540
12. Yu KD, Zhu R, Zhan M, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 2013; 19:2723-2733
13. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395-399
14. Scully R, Xie A, Nagaraju G. Molecular functions of BRCA1 in the DNA damage response. Cancer Biol Ther 2004; 3:521-527 (Pubitemid 41351121)
15. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-921 (Pubitemid 40559006)
16. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28:375-379
17. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-244
18. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2:1048-1063
19. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145-1153
20. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16:6159-6168
21. Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107:1776-1782
22. Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2:366-375
23. Vollebergh MA, Lips EH, Nederlof PM, et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011; 22:1561-1570
24. Origanti S, Cai SR, Munir AZ, et al. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 2013; 32:577-588
25. Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-873
26. Ruzankina Y, Schoppy DW, Asare A, et al. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet 2009; 41:1144-1149
27. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012; 21:614-625
28. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405-409
29. Baselga J, Gomez P, Greil R, et al. Randomized phase II study of the antiepidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586-2592
30. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615-2623
31. Shiang CY, Qi Y, Wang B, et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 2010; 123:747-755
32. Sun T, Aceto N, Meerbrey KL, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011; 144:703-718
33. Bilal E, Alexe G, Yao M, et al. Identification of the YES1 kinase as a therapeutic target in basal-like breast cancers. Genes Cancer 2010; 1:1063-1073
34. Choi YL, Bocanegra M, Kwon MJ, et al. LYN is a mediator of epithelial- mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010; 70:2296-2306
35. Tryfonopoulos D, Walsh S, Collins DM, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011; 22:2234-2240
36. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basaltype/ triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105:319-326 (Pubitemid 47596452)
37. Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triplenegative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17:6905-6913
38. Proia DA, Zhang C, Sequeira M, et al. Preclinical activity profile and therapeutic efficacy of the Hsp90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res 2013
39. Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013; 19:5505-5512.